Long‐term support by left ventricular assist device for arrhythmogenic right ventricular cardiomyopathy

• DOI: 10.1111/aor.13482
• Publication Date: 2019-05-08T14:29:23Z
• Authors: Sachito Minegishi; Osamu Kinoshita; Yasuhiro Hoshino; Hyoe Komae; Mitsutoshi Kimura; Shogo Shimada; Haruo Yamauchi; Kan Nawata; Minoru Ono
• Keywords: Adult; Male; Heart Ventricles; Disease Management; Middle Aged; 3. Good health; Prosthesis Implantation; 03 medical and health sciences; 0302 clinical medicine; Humans; Heart-Assist Devices; Arrhythmogenic Right Ventricular Dysplasia

Abstract Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heart muscle disorder characterized by enlargement, failure (HF), and arrhythmias which lead to sudden death especially in young adults. Current recommendations for management of patients with ARVC are antiarrhythmic medications, catheter ablation, implantable cardioverter defibrillator therapy prevent cardiac death. However, despite these treatments, few suffer from recurrent or HF unresponsive conventional management. Heart transplantation (HTx) preferred treatment cases, but because persistent donor shortage Japan, assist device (VAD) support has become an important option the end‐stage ARVC. Previous articles reported 4 cases successful left (LVAD), longest interval LVAD was only 333 days. We present 3 who were successfully managed implantation more than year. These unconventional examples patients, considering nature disease. The novelty should be taken context extremely long waiting period HTx Japan.